Medicina
Departamento
Maastricht University Medical Centre
Maastricht, HolandaPublicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (62)
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
2022
-
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Natural History of MYH7-Related Dilated Cardiomyopathy
Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461
-
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Journal of Hematology and Oncology, Vol. 15, Núm. 1
2021
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nature Communications, Vol. 12, Núm. 1
-
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
Cancers, Vol. 13, Núm. 17
-
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Leukemia, Vol. 35, Núm. 12, pp. 3444-3454
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
European Journal of Cancer, Vol. 151, pp. 211-220
2020
-
Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology
European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1298-1314
-
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness
Cancer Research, Vol. 80, Núm. 3, pp. 624-638
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review
Thrombosis Research
-
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Radiotherapy and Oncology, Vol. 149, pp. 84-88